CClinicalTrials.gg
RecruitingNCT05801614CarborCalUpdated Jan 2, 2024

Normalized Glucose Levels in Type 2 Diabetes With Carbohydrate or Caloric Restriction

An interventional study of Low carb diet in Diabetes Mellitus Type 2 in Obese, sponsored by Region Stockholm. Recruiting at 1 site in Sweden. Open to participants aged 24 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-01-02.

Sponsored by Region Stockholm · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Feb 2022, registered Jan 2023).
  • Started Feb 2022; still recruiting 4 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
24 Years to 70 Years
Sex
All
01

Study summary

This is a randomized controlled trial to determine whether a low-carbohydrate (LC) diet can lead to normalized blood glucose levels in patients with short duration of type 2 diabetes (T2D). Previous studies have shown that caloric restricted diet leading to weight loss can normalize blood glucose levels in approximately 50% of patients with a short duration of diabetes type 2. However, caloric restriction is difficult to maintain. Less restrictive approaches are needed. The hypothesis in this study is that Low carbohydrate diet can results in normalized blood glucose levels in T2D and can be an alternative to caloric restriction diet, both in the shorter term (3 months) and longer term (15 months). The outcome of this study leading to reduction of HbA1c is important for prevention of diabetes complications.

Read the detailed description

Background Overweight and obesity raise the risk of hyperglycemia which is among the strongest risk factors for morbidity and mortality globally, linked to type 2 diabetes (T2D) as well as, e.g., cardiovascular diseases (CVD), several cancers, dementia, complicated pregnancies and non-alcoholic fatty liver disease.1 The link between obesity, T2D and CVD is partially explained by the visceral adiposity and ectopic (e.g., hepatic) fat associated with insulin resistance, glucose intolerance, arterial stiffness, high blood pressure and dyslipidaemia constituting the metabolic syndrome.2,3 Recent studies have demonstrated that diet-induced weight loss, averaging just over 10 kg at 12-months, can effectively normalize blood glucose levels in T2D in a large proportion of patients. While energy-restrictive diets can enable rapid weight loss, any restrictive diet can be difficult to maintain over time. Strict weight loss diet is difficult to follow. Less restrictive approaches that can be adopted as part of a healthy lifestyle would be ideal.

Cardiovascular complications are the leading cause of morbidity and mortality among patients with diabetes. 29 The mechanisms of diabetes mellitus-associated progression of atherosclerosis are not fully understood. Hyperglycemia has been shown to cause increased oxidative stress arising from oxi-dative degradation of glucose metabolites. Similarly, advanced glycosylation endproducts (AGEs), which are the result of intracellular hyperglycemia, have been shown to be involved in mediating vascular damage. Furthermore hyperglycemia has been reported that to lead to a hypercoagulable state.29 Low carbohydrate diet has recently gained popularity. Rresearch questions remain on if LC diet with low GI can lead to normalization of blood glucose levels and decrease cardiovascular risk markers. The ideal energy percentage (E%) of carbohydrate in the diet for optimal glucose levels is unclear. Caloric restriction diet has shown best results for normalisation of blood glucose levels. There are no previous studies comparing LC diet with caloric restricted diet in regard to normalization of blood glucose levels. The main goal of this study is to evaluate if LC with low GI can lead to normalization or improvement of blood glucose levels in type 2 diabetes (T2D) and to explore the mechanism for normalization of blood glucose levels after LC diet and caloric restricted diet.

The main hypothesis in this study is that Low carbohydrate diet can results in normalization or improvement of blood glucose levels in patients with T2D with short duration of disease both in the shorter term (3 months) and longer term (15 months).

286 patients with type 2 diabetes will be included in this study. Patients will be randomized to a low Carb diet or a low caloric diet for 15 months.

Previous study on caloric restriction diet (DIRECT trial) showed normalization of blood glucose levels in 46% of participants after 12 months. Previous studies on LC diet have shown different results on blood glucose levels based on differences in study design. The greater the carbohydrate restriction, the greater glucose lowering effect. There is a lack of studies reporting normalisation of blood glucose levels. Therefore, it was assumed that LC dietary strategies can result in normalization of blood glucose levels in 30% of patients with T2D after 3 and 15 months. Using an online sample size calculator for a study power of 80% and alpha value of 0.05 the sample size was calculated to 143 participants in each group.

Anthropometric data and blood samples will be collected at baseline and after 3 months (initial weight loss and remission) months (continued weight loss and remission), and 15 months (weight maintenance). For security reason Hb1c and lipid status will be analyzed after changes in medication. For Standardized measurement protocols, instruments (e.g., for anthropometrics), collection tubes, etc. will be used. HbA1c, glucose, lipids and other standard biochemical variables will be measured directly on the day of the visit at the laboratories, or, for substances sensitive to batch effects (e.g., serum insulin), after collection and freezing at -80°C. Samples that are not analyzed immediately will be stored in a biobank for later use. The study will be performed in accordance with GCP.

Controlled diet that leads to weight reduction can reverse type 2 diabetes or delay the diagnosis of T2D. According to the report from the Swedish Institute for Health and Healthcare Economi (IHE) decreasing the blood sugar levels in patient with T2D will spare 800 cases of heart infarction, 500 cases of stroke, 450 cases of kidney failure and 20 cases of blindness. Delaying the diabetes diagnosis is beneficial for the patients since the diabetes complications are directly correlated to the diabetes duration. Patient with type 2 diabetes who change their diet with less carbohydrate have shown to need less insulin. The cost of diabetes disease is affected by the cost of medications and the cost of complications of diabetes. Improved knowledge about which diet can reverse T2D and improve glucose levels will in the end affect the cost for the type 2 diabetes. Dietary intervention which effectively improve blood sugar levels will have significant positive health economic effects. The result from this study will be used for diet recommendation for patients with T2D.

Both men and women will be included in the study. Sex will also be one of the factors in randomisation to assure both groups have equal percent of men and women. Gender is considered a risk factor for obesity. Previous studies have shown that being female doubles the chance of becoming overweight. It is known that lifestyle intervention programs are effective in the prevention of type 2 diabetes mellitus in high-risk populations. However, most studies report poorly about the influence of sex and/or gender effectiveness of these interventions. Male sex is acknowledged as a diabetes risk factor. Men are marginally higher affected by diabetes all over the world. They are diagnosed at younger age and at lower levels of overweight/obesity. Women on the other hand are the majority of participants in weight loss studies (This was also observed this in our study investigating the effect of intermittent fasting). Women show greater weight control involvement and thus seek medical help for weight loss therapy/surgery earlier. It is not known if men and women have different preference for LC-diet or caloric restriction as strategies for weigh maintenance. We will be able to compare the remission rate for T2D in men and women.

02

Conditions studied

  • Diabetes Mellitus Type 2 in Obese

Keywords

  • Diabetes Mellitus Type 2
  • Diet
  • Carbohydrate-Restricted
  • Caloric restriction
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 286 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Region Stockholm is the lead sponsor of 119 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • HbA1c > 48 mmol/mol (with or without medical treatment);
  • less than 6 years since the diagnosis of T2D
  • BMI ≥ 27 kg/m2 (≥ 25 kg/m2 for Asians).

Exclusion criteria

Exclusion Criteria:

  • Insulin deficiency.
  • HbA1c concentration of 12% or more (≥108 mmol/mol),
  • treatment with sulphonyl urea or sodium-glucose-cotrasporter2-inhibitor (SGL2-i),
  • myocardial infarction within the previous 6 months,
  • severe or unstable heart failure
  • other severe diseases including cancer, psychiatric/eating disorders, severe depression - substance abuse,
  • conditions that may affect the ability of patients to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
286 participants (estimated)

Study arms

  • Other
    Low Carb diet

    Participants will have acces to a plattform with recepies containing 30 g carbohydrate / day during the first three months and thereafter recepies containing 80 g carbohydrate/ day during the remaining 12 months

    Other: Low carb diet

  • Other
    Low Calori diet

    Participants will be asked to by low caloric diet replacement containing 850 kCal/day during the first 3 months, aiming for a weight loss of 10 kg during and thereafter will have access to recepies containing less calorie for weight maintenance during the remaining 12 months

    Other: Low carb diet

Interventions

  • OtherLow carb diet

    Low calori diet

    Also known as: Low calori diet

06

What researchers measure

Primary outcomes

  1. non-diabetic HbA1c

    HbA1c below 48 mmol/mol without antidiabetic medication

    Time frame: After 3 months

  2. non diabetic HbA1c

    HbA1c below 48 mmol/mol without antidiabetic medication

    Time frame: After 15 months

Secondary outcomes

  1. Changes in HbA1c

    Changes in HbA1c from base line to 3 and 15 months

    Time frame: After 3 and 15 months

  2. Percent of participants with HbA1c below 48 and 42 mmol/mol

    Number of participants with HbA1c below 48 and 42 both on and without antidiabetic medication

    Time frame: After 3 and 15 months

  3. Changes in Fasting glucose levels

    Changes in fasting plasma glucose levels after 3 and 15 months

    Time frame: After 3 and 15 months

  4. Changes in HOMA-IR

    Changes in HOMA_IR afte 3 and 15 months

    Time frame: After 3 and 15 months

  5. Changes in Insulin secretion

    Changes in Insulin secretion measured by glucagon stimulation test

    Time frame: After 3 and 15 months

07

Study locations

1 of 1 sites recruiting
  • Center for diabetes, Academic Specialist center
    Stockholm, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05801614
Lead sponsor
Region Stockholm
Responsible party
Neda Ekberg (Consultant physician, associate professor, Region Stockholm) — Principal investigator
First posted
Apr 6, 2023
Start date
Feb 28, 2022
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jan 2, 2024

Study contacts

Neda Rajamand Ekberg, M.D. PhD.
Contact
neda.ekberg@ki.se
+468-123 671 50
Katarina Fagerskiold, nurse
Contact
katarina.fagerskiold@regionstockholm.se
+468-123 671 76
Neda Rajamand Ekberg, MD, PhD
principal investigator · Region Stockholm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion